GBT

Oxbryta (voxelotor)

Sickle Cell Anemia

Quarterly Sales Approved

Exp Date

February 19, 2021 (Est)

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Oxbryta (voxelotor) for Sickle Cell Anemia Quarterly Sales (Approved)


WHAT IS THE NEXT CATALYST EVENT?

  • Quarterly Sales (Approved)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 19, 2020


PRIOR DATA/EVENTS

PRESS RELEASES

  • Q3 2020 sales $36.9M

Updated by MV

Oxbryta (voxelotor), cystic fibrosis, GBT, genetic disorder

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon